- Home
- GLPG vs DHC Comparison
GLPG vs DHC Comparison
Compare GLPG & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | DHC |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Belgium | United States |
| Employees | 452 | 585 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | DHC |
|---|---|---|
| Price | $27.73 | $9.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $36.50 | $8.00 |
| AVG Volume (30 Days) | 263.2K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.53% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.13 |
| Revenue Next Year | N/A | $7.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.62 | $3.18 |
| 52 Week High | $37.78 | $9.14 |
Technical Indicators
Market Signals| Indicator | GLPG | DHC |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 61.15 |
| Support Level | N/A | $4.10 |
| Resistance Level | $34.04 | $9.14 |
| Average True Range (ATR) | 0.56 | 0.32 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 25.33 | 96.06 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.